Navigation Links
BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
Date:3/23/2009

NEW HAVEN, Conn. and TORONTO, March 23 /PRNewswire/ -- BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics.

Dalton Medicinal Chemistry will apply their proprietary insights to the design and synthesis of new classes of compounds against selected Riboswitch targets. BioRelix will advance these compounds with their cutting edge array of biological assays and thorough knowledge of Riboswitch drug discovery and development.

Brian Dixon, BioRelix CEO commented, "We are pleased to have the opportunity to expand and renew our productive relationship with the creative team at Dalton Medicinal Chemistry. We are confident their expertise, insights and commitment to high quality medicinal chemistry, coupled with our propriety and leading position on Riboswitches, will continue to deliver value in important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to work further with BioRelix in the discovery and development of much needed new anti-infective agents. The team at BioRelix has clearly established a remarkably innovative and fundamentally groundbreaking approach to anti-infectives and we are pleased to be with them at the forefront of this medicinal chemistry and drug discovery."

About BioRelix:

BioRelix, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective product candidates based on novel patented RNA targets, termed Riboswitches, which were identified by the laboratory of BioRelix co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, Novartis Venture Fund, Aisling Capital, New Leaf Venture Partners, Elm Street Ventures and Alexandria Real Estate Equities.

About Dalton Medicinal Chemistry:

Dalton Medicinal Chemistry is a drug discovery company focused on the design, synthesis and advancement of new chemical entities in partnership with Biotech and Pharma.


'/>"/>
SOURCE Dalton Medicinal Chemistry
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
2. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
3. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
4. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
5. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
6. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. Acesys and Provid Announce Alliance for Medicinal Chemistry Services
8. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
9. MS Drug Development Agreement Based on WEHIs Medicinal Chemistry
10. Neptune Technologies expands into medicinal markets in Asia Pacific
11. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... February 11, 2016 ... or "Company") (OTCQB: PSID), a life sciences company ... its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared ... plan in January 2016, including entering into agreements ... monthly sales growth, and establishing several near-term pipeline ...
(Date:2/11/2016)... ... 11, 2016 , ... Global Stem Cells Group, ... Ecuador. The new facility will provide advanced protocols and state-of-the-art techniques in cellular ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, ...
(Date:2/10/2016)... LOUISVILLE, Ky. , Feb. 10, 2016 ... company utilizing its proprietary NeXosome® technology for early ... presentation of its most recent study by Dr. ... Hospital at the Society for Maternal Fetal Medicine,s (SMFM) ... , GA, February 1-6 th , 2016.  The presentation ...
(Date:2/10/2016)... Feb. 10, 2016  Allergan plc (NYSE: AGN ... Brent Saunders , Allergan,s CEO and President, will ... chat session at the RBC Capital Markets Healthcare Conference ... at The New York Palace Hotel in ... webcast live and can be accessed on Allergan,s Investor ...
Breaking Biology Technology:
(Date:2/9/2016)... Feb. 9, 2016 Vigilant Solutions announces today that ... (LPR) to develop a lead in a difficult homicide case. ... data to locate the suspect vehicle. Due to the ongoing ... have been omitted at the agency,s request. ... explains, "Our victim was found deceased at an intersection here ...
(Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Facial Recognition Market ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ... Market 2016-2020" report to their offering. ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ...
(Date:2/3/2016)... February 4, 2016 --> --> ... 1,351.5 M (105.0), up 1,187% compared with fourth quarter of 2014. ... SEK 517.6 M (loss: 30.0). Earnings per share increased to ... SEK 537.4 M (neg: 74.7). , --> ... amounted to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
Breaking Biology News(10 mins):